雙成藥業(002693.SZ)擬與二葉製藥簽署產品權利轉讓協議
格隆匯12月3日丨雙成藥業(002693.SZ)公佈，公司(甲方)於2019年12月03日召開第三屆董事會第三十二次會議，會議審議通過了《關於公司簽署
<產品權利轉讓協議>
的議案》，同意公司擬以人民幣5000萬元將擁有與注射用比伐蘆定有關的特定知識產權和生產技術在指定區域內的權利授予蘇州二葉製藥有限公司(“二葉製藥”,
乙方)。
比伐蘆定是一種作用可逆的特異性凝血酶抑制劑。注射用比伐蘆定的適應症是作為抗凝劑用於成人經皮冠狀動脈腔內成形術(PTCA)和經皮冠狀動脈介入治療(PCI)，以及用於PCI中有由肝素引起血小板減少(HIT)或有由肝素引起血小板減少和血栓綜合症(HITTS)風險的病人。
公司擁有與注射用比伐蘆定(“轉讓產品”、“該產品”)有關的特定知識產權，合法擁有轉讓產品的生產技術，並且於2019年1月獲得了國家藥品監督管理局頒發的《藥品註冊批件》(批准文號：國藥準字H20193019)、於2019年5月獲得海南省藥品監督管理局頒發的《藥品GMP證書》(證書編號為HI20190021)。
根據北京亞超資產評估有限公司出具的《海南雙成藥業股份有限公司擬轉讓其擁有的“注射用比伐蘆定(雙成安泰)”專有技術資產評估報告》【北京亞超評報字(2019)第A221號】(《評估報告》)，本次評估採用收益法對轉讓產品在評估基準日2019年10月31日進行評估，注射用比伐蘆定專有技術評估值為4514萬元，本次評估結論值為不含增值税轉讓價。
此次授予權利：轉讓產品在指定區域內(該區域指：中華人民共和國，包括台灣、香港特別行政區和澳門特別行政區)的所有產品權利，包括但不限於商業化權利(分銷、銷售、市場推廣、醫患教育等)、自由生產權利(乙方自行生產、委託甲方生產或者委託第三方生產)、品牌宣傳、產品再開發等；甲方除了繼續持有該產品的生產批准文號，接受且唯一為乙方生產該產品外，不再對該產品有任何其他的權利。
公司將注射用比伐蘆定有關的特定知識產權和生產技術在指定區域內的權利授予二葉製藥不會影響公司業務的正常開展，也不涉及高層人員變動等情況，交易發生後不會導致與關聯方產生同業競爭的情況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
